Treating GvHD: current challenges and newly approved drugs

Katie Gatwood

Graft versus host disease (GvHD) remains to be one of the leading causes of morbidity and mortality in patients who have undergone bone marrow transplant. Here, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, briefly discusses the challenges with current treatment options for GvHD and gives an update on newly approved drugs that can be used to effectively treat patients. This interview was recorded at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO.

Share this video  
Similar topics
Related videos
3:08
Identifying patient subgroups to improve outcome, resistance and toxicity in CAR T
John Rossi
1:53
Bringing ibrutinib to the frontline of chronic GvHD treatment
Steven Pavletic
2:39
AML complications: research into GvHD treatments
Florent Malard
2:19
The NIH Chronic GvHD Consensus Response Criteria for clinical trials
Steven Pavletic
2:31
Ibrutinib for treating chronic GvHD
Steven Pavletic
General
Ibrutinib, Ruxolitinib
HOPA 2018
Interview
21st March 2018
More from Katie Gatwood
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
Ruxolitinib and ibrutinib: the future for GvHD treatment?
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals